Header links
Intranet
Donate now
image/svg+xml Map
Contact us

Maria Camprodon Gomez

Maria Camprodon Gomez

Institutions of which they are part

Predoctoral researcher
Neurodegenerative Diseases
Vall Hebron Institut de Recerca
Internal Medicine
General Hospital
Maria Camprodon Gomez
LinkedIn
Orcid

Maria Camprodon Gomez

Maria Camprodon Gomez
LinkedIn
Orcid

Institutions of which they are part

Predoctoral researcher
Neurodegenerative Diseases
Vall Hebron Institut de Recerca
Internal Medicine
General Hospital

Projects

Advancing Parkinson's disease management: targeting autophagic-lysosomal dysfunction for innovative diagnostics and therapeutics

IP: Marta Martínez Vicente
Collaborators: José Antonio Arranz Amo, Mercedes Arrúe Gonzalo, Silvia Enriquez Calzada, Jorge Hernández Vara, Pau Sarle Valles, Eddie Pradas Gracia, Maria Camprodon Gomez, Laura Castillo Ribelles, Clara Carnicer Cáceres, Jordi Riera Heredia, Pablo Castillo Sánchez
Funding agency: Instituto de Salud Carlos III
Funding: 265000
Reference: PI24/00062
Duration: 01/01/2025 - 31/12/2027

NanoERT: nano-delivery platform for Enzyme Replacement Therapy in Parkinson's and Gaucher's disease

IP: Marta Martínez Vicente
Collaborators: Mercedes Arrúe Gonzalo, Maria Camprodon Gomez, Pablo Castillo Sánchez
Funding agency: Agència Gestió Ajuts Universitaris i de Recerca
Funding: 42000
Reference: 2024 PROD 00073
Duration: 02/12/2024 - 01/06/2026

NanoERT: nano-delivery platform for Enzyme Replacement Therapy in Parkinson´s and Gaucher's disease

IP: Marta Martínez Vicente
Collaborators: Mercedes Arrúe Gonzalo, Jorge Hernández Vara, Maria Camprodon Gomez, Jordi Riera Heredia, Pablo Castillo Sánchez
Funding agency: Fundació "La Caixa"
Funding: 24440
Reference: CI24-20222
Duration: 01/10/2024 - 30/09/2026

Malalties neurodegeneratives

IP: Miquel Vila Bover
Collaborators: Jorge Hernández Vara, Joan Compte Barrón, Marta Martínez Vicente, Jordi Bove Badell, Eddie Pradas Gracia, Maria Camprodon Gomez, Marina Lorente Picón, Laura Castillo Ribelles, Oriol de Fabregues-Boixar Nebot, Javier Hoyo Pérez, Ariadna Laguna Tuset, Malalties neurodegeneratives , Jordi Riera Heredia, Malalties neurodegeneratives , Helena Xicoy Cortada, Malalties neurodegeneratives , Marta González Sepúlveda, Joana Margalida Cladera Sastre, Annabelle Parent, Daniela Samaniego Toro, Daniela Samaniego Toro
Funding agency: Agència Gestió Ajuts Universitaris i de Recerca
Funding: 40000
Reference: 2021 SGR 00784
Duration: 01/01/2022 - 30/06/2025

Related news

Jocs de taula creats durant el projecte

2nd edition of the citizen science project with Parkinson's patients and young people ends

The initiative seeks to raise awareness of the disease and promote the well-being of those affected, while fostering empathy and scientific vocations among young people.

Pacient d'un assaig clínic a la consulta

VHIR exceeds 700 active clinical trials to achieve new therapies for patients

On World Clinical Trials Day, we highlight some of the studies we have participated in that confirm the efficacy of new drugs, allowing their approval by regulatory agencies.

Infermera i pacient de Parkinson amb teràpia subcutània

A new therapeutic strategy improves the control of motor symptoms in Parkinson's disease

Vall d'Hebron has participated in a phase III clinical trial which confirmed the efficacy and safety of subcutaneous infusion of levodopa therapy.

See more

Related professionals

Carmen Folch Badiella

Carmen Folch Badiella

Research technician
Pneumology
Read more
Anna Motger Albertí

Anna Motger Albertí

Research technician
Psychiatry, Mental Health and Addictions
Read more
Fernando Moreno Flores

Fernando Moreno Flores

Clinical Biochemistry, Drug Delivery & Therapy (CB-DDT)
Read more
Abigail Mora Sanz

Abigail Mora Sanz

Predoctoral researcher
Psychiatry, Mental Health and Addictions
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.